Tetramethylcyclopropyl analogue of a leading antiepileptic drug, valproic acid. Synthesis and evaluation of anticonvulsant activity of its amide derivatives

Journal of Medicinal Chemistry

Volumn 47, Issue 17, 2004, Pages 4316-4326

  Sobol, Eyal ^a   Bialer, Meir ^a,b   Yagen, Boris ^a,b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

2,2,3,3 TETRAMETHYLCYCLOPROPANECARBONYLUREA; AMIDE; ANTICONVULSIVE AGENT; CYCLOPROPANE DERIVATIVE; N METHOXY 2,2,3,3 TETRAMETHYLCYCLOPROPANECARBOXAMIDE; UNCLASSIFIED DRUG; UREA DERIVATIVE; VALPROIC ACID; VALPROIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM; DOSE RESPONSE; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; ELECTRIC SHOCK; HUMAN; LIVER TOXICITY; NONHUMAN; RAT; SEIZURE; SIDE EFFECT; TERATOGENICITY;

ANIMALS; ANTICONVULSANTS; CONVULSANTS; CYCLOPROPANES; ELECTROSHOCK; MICE; PENTYLENETETRAZOLE; POLYUNSATURATED ALKAMIDES; RATS; SEIZURES; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP; UREA; VALPROIC ACID;

EID: 3843141802     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0498351     Document Type: Article

References (64)

1. McNamara, O. J. Drugs Effective in the Therapy of the Epilepsies. In The Pharmacological Basis of Therapeutics, 10th ed.; Hardman, J. G., Limbird, L. E., Gilman, A. G., Eds; The McGraw-Hill Companies: New York, 2001; pp 521-548.
2. Bourgeois, F. D. B. Valproic Acid: Clinical Efficacy and Use in Epilepsy. In Antiepileptic Drugs, 5th ed.; Levy, R. H., Mattson, R. H., Meldrum, B. S., Perucca, E., Eds.; Lippincott Williams & Wilkins Publishers: New York, 2002; pp 808-817.
3. Silberstein, D. S. Valproic Acid: Clinical Efficacy and Use in Other Neurological Disorders. In Antiepileptic Drugs, 5th ed.; Levy, R. H., Mattson, R. H., Meldrum, B. S., Perucca, E., Eds.; Lippincott Williams & Wilkins Publishers: New York, 2002; pp 818-827.
4. Swann, C. A. Valproic Acid: Clinical Efficacy and Use in Psychiatric Disorders. In Antiepileptic Drugs, 5th ed.; Levy, R. H., Mattson, R. H., Meldrum, B. S., Perucca, E., Eds.; Lippincott Williams & Wilkins Publishers: New York, 2002; pp 828-836.
5. Blaheta, R. A.; Nau, H.; Michaelis, M.; Cinatl, J., Jr. Valproate and Valproate-Analogues: Potent Tools To Fight against Cancer. Curr. Med. Chem. 2002, 9, 1417-1433.
6. Kaneko, S.; Battino, D.; Anderman, E.; Wada, K.; Kan, R.; Takeda, A.; Nakane, Y.; Ogawa, Y.; Avanzini, G.; Fumarola, C.; Granata, T.; Molteni, F.; Pardi, G.; Minotti, L.; Canger, R.; Dansky, L.; Oguni, M.; Lopes-Cendas, I.; Sherwin, A.; Andermann, F.; Seni, M. H.; Okada, M.; Teranishi, T. Congenital Malformations Due to Antiepileptic Drugs. Epilepsy Res. 1999, 33, 145-158.
7. Konig, A. S.; Siemes, H.; Blaker, F.; Boenigk, E.; Grop-Selbeck, G.; Hanefeld, F.; Haas, N.; Kohler, B.; Koelfen, W.; Krointhenberg, R.; Kurek, E.; Lenard, H. G.; Penin, H.; Penzien, J. M.; Shumke, W.; Schultze, C.; Stefan, U.; Stute, M.; Traus, M.; Weinmann, H. M.; Scheffner, D. Severe Hepatotoxicity during Valproate Therapy: An Update and Report of Eight New Fatalities. Epilepsia 1994, 35, 1005-1015.
8. Konig, A. S.; Shenk, M.; Sick, C.; Holm, E.; Heubner, C.; Weiss, A.; Konig, I.; Hehlmann, R. Fatal Liver Failure Associated with Valproate Therapy in Patients with Friedreich's Disease: Review of Valproate Hepatotoxicity in Adults. Epilepsia 1999, 40, 1036-1040.
9. Sussman, N. M.; McLean, L. W., Jr. A Direct Hepatotoxic Effect of Valproic Acid. JAMA, J. Am. Med. Assoc. 1979, 242, 1173-1174.
10. Zimmerman, H. J.; Ishak, K. G. Valproate-Induced Hepatic Injury: Analysis of 23 Fatal Cases. Hepatology 1982, 591-597.
11. Rettie, A. E.; Rettenmeir, A. W.; Howald, W. N.; Baillie, T. A. Cytochrome P450 Catalyzed Formation of 4-ene-VPA, a Toxic Metabolite of Valproic Acid. Science 1987, 235, 890-893.
12. Baillie, A. T. Metabolic Activation of Valproic Acid and Drug-Mediated Hepatotoxicity. Role of the Terminal Olefin, 2-n-Propyl-4-pentenoic Acid. Chem. Res. Toxicol. 1988, 1, 195-199.
13. Nau, H.; Loscher, W. Pharmacological Evaluation of Various Metabolites and Analogues of Valproic Acid: Teratogenic Potencies in Mice. Fundam. Appl. Toxicol. 1986, 6, 669-676.
14. Isoherranen, N.; Yagen, B.; Bialer, M. New CNS-Active Drugs Which Are Second-Generation Valproic Acid: Can They Lead to the Development of a Magic Bullet? Curr. Opin. Neurol. 2003, 16, 203-211.
15. Liu, M. J.; Pollack, G. M. Pharmacokinetics and Pharmacodynamics of Valproate Analogues in Rats: IV. Antiepileptic Action and Neurotoxicity of Octanoic Acid, Cyclohexanecarboxylic Acid, and 1-Methyl-1-cyclohexanecarboxylic Acid. Epilepsia 1994, 35, 234-243.
16. Morre, M.; Keane, P. E.; Vernieres, J. C.; Simiand, J.; Roncucci, R. Valproate: Recent Findings and Perespectives. Epilepsia 1984, 25 (Suppl. 1), S5-S9.
17. Keane, P. E.; Simiand, J.; Mendes, E.; Santucci, V.; Morre, M. The Effects of Analogues of Valproic Acid on Seizures Induced by Pentylenetetrazole and GABA Content in Brain of Mice. Neuropharmacology 1983, 22, 875-879.
18. Zirvi, K. A.; Jarboe, C. H. Synthesis and Neuropharmacology of Cyclobutanecarboxylic Acid Derivatives. Farmaco, Ed. Sci. 1976, 31, 152-158.
19. Brana, M. F.; Martinez, M.; Garrido, J.; Roldan, C. M. Synthesis and Pharmacological Activity of the Cyclic Homologues of Dipropylacetic Acid. An. Quim. 1983, 79, 47-51.
20. Scott, K. R.; Moore, J. A.; Zalucky, T. B.; Nicholson, J. M.; Lee, J. A. M.; Hinko, C. N. Spiro[4.5] and Spiro[4.6] Carboxylic Acids: Cyclic Analogues of Valproic Acid. Synthesis and Anticonvulsant Evaluation. J. Med. Chem. 1985, 28, 413-417.
21. Liu, M. J.; Scott, K. R.; Pollack, G. M. Pharmacokinetics and Pharmacodynamics of Valproate Analogues in Rats. I. Spiro-[4.6]Undecane-2- Carboxylic Acid. Epilepsia 1990, 31, 465-473.
22. Abbott, S. F.; Acheampong, A. A. Quantitative Structure-Anticonvulsant Activity Relationships of Valproic Acid, Related Carboxylic Acids and Tetrazoles. Neuropharmacology 1988, 27, 287-294.
23. Palaty, J.; Abbott, F. S. Structure-Activity Relationships of Unsaturated Analogues of Valproic Acid. J. Med. Chem. 1995, 38, 3398-3406.
24. Bojic, U.; Elmazar, M. M. A.; Hauck, R. S.; Nau, H. Further Branching of Valproate-Related Carboxylic Acids Reduces the Teratogenic Activity, but Not the Anticonvulsant Effect. Chem. Res. Toxicol. 1996, 9, 866-870.
25. Haj-Yehia, A.; Bialer, M. Structure-Pharmacokinetic Relationships in a Series of Valpromide Derivatives with Antiepileptic Activity. Pharm. Res. 1989, 6, 683-689.
26. Haj-Yehia, A.; Bialer, M. Structure-Pharmacokinetic Relationships in a Series of Short Fatty Acid Amides That Possess Anticonvulsant Activity. J. Pharm. Sci. 1990, 79, 719-724.
27. Tang, W.; Borel, G. A.; Fujimiya, T.; Abbott, S. F. Fluorinated Analogues as Mechanistic Probes in Valproic Acid Hepatotoxicity: Hepatic Microvesicular Steatosis and Glutatione Status. Chem. Res. Toxicol. 1995, 8, 671-682.
28. Tang, W.; Palaty, J.; Abbott, F. S. Time Course of α-Fluorinated Valproic Acid in Mouse Brain and Serum and Its Effect on Synaptosomal γ-Aminobutyric Acid Levels in Comparison to Valproic Acid. J. Pharmacol. Exp. Ther. 1997, 282, 1163-1172.
29. Grillo, M. P.; Chiellini, G.; Tonelli, M.; Benet, L. Z. Effect of α-Fluorination of Valproic Acid on Valproyl-S-Acyl-CoA Formation in Vivo in Rats. Drug Metab. Dispos. 2001, 2, 1210-1215.
30. Elmazar, M. M. A.; Hauck, R. S.; Nau, H. Anticonvulsant and Neurotoxic Activities of Twelve Analogues of Valproic Acid. J. Pharm. Sci. 1993, 82, 1255-1258.
31. Loscher, W.; Nau, H. Pharmacological Evaluation of Various Metabolites and Analogues of Valproic Acid. Neuropharmacology 1985, 24, 427-435.
32. Badir, K.; Haj-Yehia, A.; Vree, B. T.; Van Der Kleijn, E.; Bialer, M. Pharmacokinetics and Anticonvulsant Activity of Three Monoesteric Prodrugs of Valproic Acid. Pharm. Res. 1991, 8, 750-753.
33. Redecker, C.; Altrup, U.; Hoppe, D.; Dusing, R.; Speckmann, E. J. Effects of valproate derivatives I. Antiepileptic Efficacy of Amides, Structural Analogues and Esters. Neuropharmacology 2000, 39, 254-266.
34. Pisani, F.; Fazio, A.; Oteri, G.; Di Perri, R. Dipropylacetic Acid Plasma Levels; Diurnal Fluctuations during Chronic Treatment with Dipropylacetamide. Ther. Drug Monit. 1981, 3, 297-301.
35. Bialer, M.; Rubinstein, A.; Raz, I.; Abramsky, O. Pharmacokinetics of Valpromide after Oral Administration of a Solution and a Tablet to Healthy Volunteers. Eur. J. Clin. Pharmacol. 1984, 27, 501-503.
36. Haj-Yehia, A.; Hadad, S.; Bialer, M. Pharmacokinetic Analysis of the Structural Requirements for Forming "Stable" Analogues of Valpromide. Pharm. Res. 1992, 9, 1058-1063.
37. Bialer, M.; Hadad, S.; Kadry, B.; Abdul-Hai, A.; Haj-Yehia, A.; Sterling, J.; Herzig, Y.; Yagen, B. Pharmacokinetic Analysis and Antiepileptic Activity of Tetramethylcyclopropane Analogues of Valpromide. Pharm. Res. 1996, 13, 284-289.
38. Tantisira, B.; Tantisira, M. H.; Patarapanich, C.; Sooksawate, T.; Chunngam, T. Preliminary Evaluation of Anticonvulsant Activity of a Valproic Acid Analogue: N-(2-Propylpentanoyl)-urea. Res. Commun. Mol. Pathol. Pharmacol. 1997, 97, 151-164.
39. Levi, M.; Yagen, B.; Bialer, M. Pharmacokinetics and Antiepileptic Activity of Valproyl Hydroxamic Acid Derivatives. Pharm. Res. 1997, 14, 213-217.
40. Hadad, S.; Bialer, M. Pharmacokinetic Analysis and Antiepileptic Activity of Two New Isomers of N-Valproyl Glycinamide. Biopharm. Drug Dispos. 1997, 18, 557-566.
41. Nau, H.; Ellerbeck, U.; Radatz, M. A New Analogue of Valproic Acid with Improved Anticonvulsant Properties and Low Teratogenic and Neurotoxic Potential in Experimental Animals. Epilepsia 1998, 39 (Suppl. 6), 42.
42. Isoherranen, N.; White, H. S.; Finnell, R. H.; Yagen, B.; Woodhead, J. H.; Bennett, G. D.; Wilcox, K. S.; Barton, M. E.; Bialer, M. Anticonvulsant Profile and Teratogenicity of N-Methyl-tetramethylcyclopropyl Carboxamide: A New Antiepileptic Drug. Epilepsia 2002, 43, 115-126.
43. Isoherranen, N.; Yagen, B.; Woodhead, J. H.; Spiegelstein, O.; Blotnik, S.; Wilcox, S. K.; Finnell, R. H.; Bennett, D. G.; White, S. H.; Bialer, M. Characterization of the Anticonvulsant Profile and Enantioselective Pharmacokinetics of the Chiral Valproylamide Propylisopropyl Acetamide in Rodents. Br. J. Pharmacol. 2003, 138, 602-613.
44. Gianolla, L. I.; Lamartina, L.; de Caro, V. Synthesis and Characterization of Aminoacidic Pro-Drugs of Valproic Acid. Pharmazie 1998, 53, 829-834.
45. Hadad, S.; Bialer, M. Pharmacokinetic Analysis and Antiepileptic Activity of N-Valproyl Derivatives of GABA and Glycine. Pharm. Res. 1995, 12, 905-910.
46. Isoherranen, N.; Woodhead, H. J.; White, H. S.; Bialer, M. Anticonvulsant Profile of Valrocemide (TV1901): A New Antiepileptic Drug. Epilepsia 2001, 42, 831-836.
47. Isoherranen, N.; Levy, R. H.; Yagen, B.; Woodhead, H. J.; White, H. S.; Bialer, M. Metabolism of a New Antiepileptic Drug, N-Methyl- tetramethylcyclopropanecarboxamide, and Anticonvulsant Activity of Its Metabolites. Epilepsy Res. 2004, 58, 1-12.
48. Furniss, B. S.; Hannaford, A. J.; Smith, P. W. G.; Tatchell, A. R. Vogel's Textbook of Practical Organic Chemistry; Prentice Hall: New York, 1989; pp 720-723.
49. Belleau, B.; Malek, G. A New Convenient Reagent for Peptide Synthesis. J. Am. Chem. Soc. 1968, 90, 1651.
50. Isoherranen, N.; Yagen, B.; Spiegelstein, O.; Finnel, H. R.; Merriweather, M.; Woodhead, H. J.; Wlodarczyk, B.; White, H. S.; Bialer, M. Anticonvulsant Activity, Teratogenicity and Pharmacokinetics of Novel Valproyltaurinamide Derivatives in Mice. Br. J. Pharmacol. 2003, 139, 755-764.
51. Spielman, M. A.; Geiszler, A. O.; Close, W. J. Anticonvulsant Drugs. II. Some Acetyureas. J. Am. Chem. Soc. 1948, 70, 4189-4191.
52. Everett, G. M.; Richards, R. K. Pharmacological Studies of Phenylacetylurea (Phenurone), an Anticonvulsant Drug. J. Pharmacol. Exp. Ther. 1952, 106, 303-313.
53. Swinyard, E. A.; Toman, J. E. P. A Comparison of the Anticonvulsant Action of Some Phenylhydantoins and Their Corresponding Phenylacetylureas. J. Pharmacol. Exp. Ther. 1950, 100, 151-157.
54. Gibbs, F. A.; Everett, G. M.; Richards, R. K. Phenurone in Epilepsy. Dis. Nerv. Syst. 1949, 10, 47-49.
55. Livingston, S.; Pauli, L. L. Phenacemide in the Treatment of Epilepsy. N. Engl. J. Med. 1957, 256, 588-592.
56. White, H. S.; Woodhead, J. H.; Wilcox, K. S.; Stables, J. P.; Kupferberg, H. J.; Wolf, H. H. Discovery and Preclinical Development of Antiepileptic Drugs. In Antiepileptic Drugs, 5th ed.; Levy, R. H., Mattson, R. H., Meldrum, B. S., Perucca, E., Eds.; Lippincott Williams & Wilkins Publishers: New York, 2002; pp 36-48.
57. Zirvi, K. A.; Dar, M. S.; Fakouhi, T. Biochemorphology of Cyclobutanecarbonylureas. J. Pharm. Sci. 1975, 64, 649-651.
58. Zirvi, K. A.; Fakouhi, T. Synthesis and Neuropharmacology of Cyclopropanecarbonylureas. Farmaco, Ed. Sci. 1978, 33, 288-294.
59. Zirvi, K. A.; Fakouhi, T. Synthesis and Neuropharmacology of Cyclobutanecarbonylureas. Farmaco, Ed. Sci. 1979, 34, 170-177.
60. Masereel, B.; Rolin, S.; Abbate, F.; Scozzafava, A.; Supuran, T. C. Carbonic Anhydrase Inhibitors: Anticonvulsant Sulfonamides Incorporating Valproyl and Other Lipophilic Moieties. J. Med. Chem. 2002, 45, 312-320.
61. Losher, W.; Potschka, H. Role of Multidrug Transporters in Pharmacoresistance to Antiepileptic Drugs. J. Pharmacol. Exp. Ther. 2002, 301, 7-14.
62. Tew, K. D.; Houghton, P. J.; Houghton, J. A. Modulation of P-Glycoprotein-Mediated Multidrug Resistance. In Preclinical and Clinical Modulation of Anticancer Drugs; Tew, K. D., Houghton, P. J., Houghton, J. A., Eds.; CRC Press: Boca Raton, FL, 1993; pp 125-196.
63. Jezequel, S. G. Central Nervous System Penetration of Drugs: Importance of Physicochemical Properties. In Progress in Drug Metabolism; Gibson, G. G., Ed.; Taylor & Francis, London, 1992; pp 141-178.
64. Camerman, A.; Camerman, N. Stereochemical Similarities in Chemically Different Antiepileptic Drugs. In Antiepileptic Drugs, 1st ed.; Glaser, G. H., Penry, J. K., Woodbury, D. M., Eds.; Raven Press: New York, 1980; pp 223-231.